

## High-Dose Inhaled Nitric Oxide for Drug-Resistant Pneumonia

*Prelims: Current events of national and international importance | Health*

### Why in News?

Recently, researchers reported that high-dose inhaled nitric oxide reduced drug-resistant bacteria in a large-animal ICU model and was found safe in early human testing.

### Pneumonia

- It is an **infection of the lungs that causes inflammation of air sacs** (alveoli) and accumulation of fluid or pus in the lungs.
  - **Type** - It can range from mild to severe and may be life-threatening, and can affect one or both lungs.
- **Causes - Bacterial causes** - *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Legionella pneumophila*, *Mycoplasma pneumoniae*.
- **Viral causes** - Influenza, COVID-19, respiratory syncytial virus, human metapneumovirus.
- **Fungal cause** - *Pneumocystis jirovecii* (PCP), especially in immunocompromised (weakened immune system) individuals.
- **Symptoms** - Fever, chills, cough with mucus, breathlessness, chest pain, fatigue, loss of appetite, bluish lips/nails, nausea/vomiting in children, and confusion in the elderly.
- **Risk factors** - Chronic diseases, weak immunity, smoking, pollutant exposure, indoor biomass fuel use, crowded living conditions, parental smoking.
- **Transmission** - Community-acquired, hospital/ventilator-associated, or aspiration of food/liquids into lungs.
- **Diagnosis** - Clinical exam, imaging, blood tests, sputum test, pulse oximetry.
- **Treatment** - Antibiotics/other drugs, pain and fever medicines, oxygen or IV fluids in severe cases, hospitalisation if needed, rest and hydration.

## Nitric Oxide Therapy for Drug-Resistant Pneumonia

- **Caused by** - *Drug-resistant Pseudomonas aeruginosa*.
  - Causes about one in five hospital pneumonias and resists multiple drugs.
- **Nitric oxide** - Naturally produced by the human body.
- **Medical use** - Low doses are used to widen blood vessels in acute respiratory failure.
- **Key Findings** - *High-dose inhaled nitric oxide (300 ppm) reduced lung bacterial counts by 99%* in ventilated pigs with multidrug-resistant pneumonia.
- Improved oxygenation and lung function and reduced need for blood pressure drugs.
- **Human Testing** - Phase-1 human study showed no serious adverse effects in healthy volunteers.
- Feasibility tested in critically ill ICU patients without immediate serious complications.
- **Risk and Limitations - Potential toxic effects** - Elevated methemoglobin and direct lung injury.
- Bacterial rebound is possible after stopping treatment.
- Long-term benefits are not proven and require clinical efficacy trials.
- **Practical barriers** - Requires specialised equipment, trained staff, and continuous monitoring for high-dose delivery.

## Reference

[TH | High-Dose Inhaled Nitric Oxide for Drug-Resistant Pneumonia](#)